IceCure Medical (ICCM) Return on Capital Employed (2021 - 2026)

IceCure Medical (ICCM) has 6 years of Return on Capital Employed data on file, last reported at 178.4% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 178.4%, down 5104.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 178.4% (down 5104.0% YoY), and the FY2025 annual result was 179.52%, up 471.0% from the prior year.
• Return on Capital Employed climbed to 178.4% in Q1 2026 per ICCM's latest filing, from 156.27% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 494.47% in Q2 2025 and troughed at 160.48% in Q3 2024.
• A 5-year average of 34.49% and a median of 21.72% in 2022 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed plunged 11129 bps in 2023, then soared 64355 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 0.39% in 2022, then plunged by 28662 bps to 110.9% in 2023, then jumped by 268 bps to 186.57% in 2024, then decreased by 16 bps to 156.27% in 2025, then gained by 14 bps to 178.4% in 2026.
• Business Quant data shows ICCM's Return on Capital Employed at 178.4% in Q1 2026, 156.27% in Q4 2025, and 217.39% in Q3 2025.